CDKN2A and cancer: A hereditary cancer screening panel (ATM (NM_000051.3), BRCA1 (NM_007294.3), BRCA2 (NM_000059.3), CDKN2A (NM_058195.3), CDKN2A (NM_000077.4), EPCAM (NM_002354.2), MLH1 (NM_000249.3), MSH2 (NM_000251.2), MSH6 (NM_000179.2), PALB2 (NM_024675.3), PMS2 (NM_000535.5), STK11 (NM_000455.4), TP53 (NM_000546.5)) was subsequently performed which did not identify any genetic aberrations.